Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

What Is The Risk Of Obesity While Taking Antidepressant Drugs?
Cross-sectional studies have reported an association between major depressive episode (MDE) and obesity. The objective of this longitudinal analysis was to determine whether MDE increase the risk of becoming obese over a 10-year period. Data from the Canadian National Population Health Survey (NPHS) were used, a longitudinal study of a representative cohort of household residents in Canada. The incidence of obesity, defined as a body mass index (BMI) of 30, was evaluated in respondents who were 18 years or older at the time of a baseline interview in 1994. MDE was assessed using a brief diagnostic instrument.

A 'Heart Healthy' Diet And Ongoing, Moderate Physical Activity May Protect Against Cognitive Decline
Eating a "heart healthy" diet and maintaining or increasing participation in moderate physical activity may help preserve our memory and thinking abilities as we age, according to new research reported today at the Alzheimer"s Association 2009 International Conference on Alzheimer"s Disease (ICAD 2009) in Vienna.
News of the day
Health Professions Council Take Advice Of Psychology Experts
The British Psychological Society has today welcomed the announcement by the Health Professions Council (HPC) to set high entry level qualifications for psychologists to be admitted to the forthcoming statutory register of Practitioner Psychologists.
Cardiovascular

Diabetes Drug Shows MS Potential

A small trial testing the benefits in multiple sclerosis (MS) of a drug used to treat type II diabetes, in combination with beta-interferon-1a, has been shown to potentially prevent brain cell loss. The results of the trial in 21 people investigating the effects of pioglitazone (also known as Actos) were published last month in the Journal of Neuroimmunology. Although the results of the trial showed some evidence of less damage in the brains of people with MS, there were too few people in the study to determine whether this effect was real. Dr. Susan Kohlhaas, Research Communications Officer at the MS Society said, "These results suggest that pioglitazone may have some benefit in combination with beta-interferon for people with relapsing remitting MS, but this trial is not large enough to determine exactly what that benefit will be. She added, "A larger clinical trial is needed to decide whether or not pioglitazone will be of benefit to people with MS." Multiple Sclerosis Society


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009